Literature DB >> 29520877

The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population.

Carolina Lavigne-Moreira1, Vanessa D Marques1, Marcus V M Gonçalves2, Mauricio F de Oliveira1, Pedro J Tomaselli1, José C Nunez3, Osvaldo J M do Nascimento4, Amilton A Barreira1, Wilson Marques1.   

Abstract

To present the genetic heterogeneity of a sample of the Brazilian population with transthyretin (TTR) mutations. This cohort study was descriptive and retrospective, and enrolled patients with peripheral neuropathy of unknown cause that were found to have a mutation in the TTR gene during the process of etiological investigation, between July 1997 to January 2016. Over the study period, 129 point mutations were identified in 448 tested patients, of whom 128 were of Brazilian origin. The TTR Val30Met mutation was identified in 116 patients (90.6%); while 7 (4.7%) patients had a pathogenic non-TTR mutation and 7 (4.7%) carried non-pathogenic mutations (4.7%). The four non-TTRMet30 pathogenic mutations were TTR Aps38Tyr; TTR Ile107Val; TTR Val71Ala; and TTR Val122Ile. In the non-pathogenic group, we only found two mutations, including TTR Gly6Ser and TTR Thr119Thr. Our study depicts a scenario of greater genetic heterogeneity among Brazilian hereditary transthyretin amyloidosis (hATTR) patients with familial amyloidotic polyneuropathy (FAP). We expect that this number will grow fast over a short period of time, due to increasing availability of genetic tests, increasing knowledge of the disease and the multivariate origin of our population.
© 2018 Peripheral Nerve Society.

Entities:  

Keywords:  ATTR, transthyretin amyloidosis; Brazilian; familial amyloid polyneuropathy

Mesh:

Substances:

Year:  2018        PMID: 29520877     DOI: 10.1111/jns.12259

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  3 in total

1.  Prevalence and Outcomes of p.Val142Ile TTR Amyloidosis Cardiomyopathy: A Systematic Review.

Authors:  Pranav Chandrashekar; Laith Alhuneafat; Meghan Mannello; Lana Al-Rashdan; Morris M Kim; Jason Dungu; Kevin Alexander; Ahmad Masri
Journal:  Circ Genom Precis Med       Date:  2021-08-31

2.  Variant Transthyretin Amyloidosis (ATTRv) in Hungary: First Data on Epidemiology and Clinical Features.

Authors:  Zoltán Pozsonyi; Gergely Peskó; Hedvig Takács; Dorottya Csuka; Viktória Nagy; Ágnes Szilágyi; Lidia Hategan; Balázs Muk; Beáta Csányi; Noémi Nyolczas; Lívia Dézsi; Judit Mária Molnár; Anita Csillik; Katalin Révész; Béla Iványi; Fruzsina Szabó; Krisztián Birtalan; Tamás Masszi; Zsuzsanna Arányi; Róbert Sepp
Journal:  Genes (Basel)       Date:  2021-07-28       Impact factor: 4.096

Review 3.  RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs.

Authors:  Sarah Bajan; Gyorgy Hutvagner
Journal:  Cells       Date:  2020-01-07       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.